Emergent BioSolutions (EBS) Misses Q4 EPS by 16c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.87 +4.89%
EPS Growth %: -138.7%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -138.7%
Financial Fact:
Interest expense: -2.05M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q4 EPS of $1.57, $0.16 worse than the analyst estimate of $1.73. Revenue for the quarter came in at $360.4 million versus the consensus estimate of $357.41 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- Meta bull case increasingly playing out, Mizuho says
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
